Summit Therapeutics shares are trading higher after the company announced the publication of primary analysis results from the global Phase III HARMONi clinical trial in The Lancet Oncology. Bernstein upgraded the stock from Underperform to Market Perform and raised its price target from $9.8 to $11.9.